These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8457659)

  • 1. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review.
    Nieuwenhuizen W
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):93-6. PubMed ID: 8457659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular markers for the blood coagulation and fibrinolysis].
    Okajima K
    Rinsho Byori; 2001 Mar; Suppl 115():74-90. PubMed ID: 11391940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
    Koga S
    Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
    Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
    Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are fibrin-related markers useful for the diagnosis of thrombosis?
    Wada H; Sakuragawa N
    Semin Thromb Hemost; 2008 Feb; 34(1):33-8. PubMed ID: 18393141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
    Dempfle CE
    Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
    Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
    Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Soluble fibrin monomer complexes in thromboembolism].
    Gryglik J
    Przegl Lek; 1982 Sep; 39(8):551-3. PubMed ID: 6753042
    [No Abstract]   [Full Text] [Related]  

  • 10. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma.
    Nieuwenhuizen W; Hoegee-De Nobel E; Laterveer R
    Thromb Haemost; 1992 Sep; 68(3):273-7. PubMed ID: 1440491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of hemostatic molecular marker].
    Wada H; Ioka M
    Rinsho Byori; 1997 Apr; 45(4):310-4. PubMed ID: 9136593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women.
    Peverill RE; Teede HJ; Malan E; Kotsopoulos D; Smolich JJ; McGrath BP
    Clin Sci (Lond); 2007 Nov; 113(9):383-91. PubMed ID: 17608627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
    Okajima K; Uchiba M; Murakami K; Okabe H; Takatsuki K
    Am J Hematol; 1996 Mar; 51(3):186-91. PubMed ID: 8619398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the pro-thrombotic state in CAPD patients.
    Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
    Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Soluble fibrin is not excreted in urine and its plasma level is elevated in nephrotic syndrome].
    Morikawa T; Yamashiro Y; Okano K; Kasamatsu M; Sugai H; Kitamura H; Ohba I; Hotta O; Taguma Y; Sakurai J; Kitamoto Y
    Rinsho Byori; 2009 Apr; 57(4):319-23. PubMed ID: 19489432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders.
    Bos R; Laterveer-Vreeswijk GH; Lockwood D; Szewczyk K; Nieuwenhuizen W
    Thromb Haemost; 1999 Jan; 81(1):54-9. PubMed ID: 9974375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
    McCarron BI; Marder VJ; Francis CW
    Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of soluble fibrin in plasma by affinity chromatography--a comparative study with desAA-fibrin, desAABB-fibrin and fibrinogen.
    Thiel W; Delvos U; Müller-Berghaus G
    Thromb Haemost; 1985 Aug; 54(2):533-8. PubMed ID: 4082091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Simultaneous quantification of soluble fibrin and D-dimer in blood plasma for the assessment of the threat of thrombosis].
    Lugovskii EV; Kolesnikova IN; Platonova TN; Lugovskaia NE; Litvinova LM; Kostiuchenko EP; Chernyshenko TM; Ganova LA; Spivak NIa; Komisarenko SV
    Klin Med (Mosk); 2013; 91(11):38-44. PubMed ID: 25696964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of hemostatic molecular markers for diagnosis of thrombosis].
    Wada H; Sakakura M; Nobori T; Shiku H
    Rinsho Byori; 2000 Apr; 48(4):301-7. PubMed ID: 10810874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.